Jun 15, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Endo Pharmaceuticals Completes Next Step In Regulatory Process For FORTESTA™ For Men
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2226126" data-attributes="member: 124445"><p>Endo Pharmaceuticals (Nasdaq: ENDP) has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months...<a href="http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/M5lyyHO9z9c" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/M5lyyHO9z9c/3FJj" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2226126, member: 124445"] Endo Pharmaceuticals (Nasdaq: ENDP) has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months...[URL="http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/0/da"][IMG]http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/1/da"][IMG]http://feedads.g.doubleclick.net/~a/gm433ZkcQXTlPWYkS4Tb29QNAAE/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/M5lyyHO9z9c[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/M5lyyHO9z9c/3FJj]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top